Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)
Ultra-low-dose nivolumab significantly improves OS versus chemotherapy in pretreated solid tumors, with fewer severe toxicities and better QoL. These findings support re-evaluation of ICI dosing strategies and may enhance global access.
Authors
- A. Janu
- Purvi Haria (ORCID: https://orcid.org/0000-0003-1588-9722)
- A. Ramaswamy
- Arpita Sahu (ORCID: https://orcid.org/0000-0002-6621-0807)
- Trupti Pai
- Vijayalakshmi Mathrudev
- Sachin Dhumal (ORCID: https://orcid.org/0000-0002-0564-9429)
- Arvind Vaidyanathan
- Sandeep Gedela
- P. Bhargava
- N. Purandare
- Ankush Shetake
- Rajiv Kumar (ORCID: https://orcid.org/0000-0003-0363-3287)
- Minit Shah
- Shital Chavan
- Vikas Sureshchand Ostwal
- Nivedita Chakrabarty
- Mehta Sa
- Kavita Nawale
- S. Shah
- Shripad Banavali
- Vanita Noronha
- Savita Gaikwad
- Ravi Narayan
- Kumar Prabhash
- Charushila Deshmukh
- Ravi Ingale
- Nandini Menon
- Rajendra A. Badwe
- Vijay Patil
- Laxman Sahu
- Mehak Trikha
Institutions
- Homi Bhabha National Institute (IN)
- Tata Memorial Hospital (IN)
- P. D. Hinduja Hospital and Medical Research Centre (IN)
- Aditya Jyot Eye Hospital (IN)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2026-01-28
- DOI
- https://doi.org/10.1200/jco-25-01546
- Citations
- 2
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 48.39